Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Osteosarcoma 1Neoplasms 1Meningeal Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Gemcitabine 6Cisplatin 6Bortezomib 6venetoclax 5elotuzumab 4isatuximab 3blinatumomab 3Vincristine 3Radiotherapy 3Prednisone 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2ixazomib 2dexamethasone 21-phosphate 2cabazitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × aldesleukin × Clear all
NCT01883297 2024-09-05

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

University Health Network, Toronto

Phase 1 Active not recruiting
3 enrolled
Gynecologic

Fallopian Tube Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡